Latest Biotechnology, Pharmaceutical and Healthcare News - Page: 5 from BioPortfolio

Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs

Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs, states a new report by research and consulting firm GBI Research. The new report* shows that existing cervical cancer vaccines, GSK’s Cervarix and Merck’s Gardasil, are competing against each other for valuable m...

Drugs under development to treat those affected by acute spinal cord injuries are not expected to emerge within the current decade

Drugs under development to treat those affected by acute spinal cord injuries are not expected to emerge within the current decade, leaving the market largely open to new entrants, according to a new report issued by pharmaceuticals intelligence provider GlobalData. The new report* shows that there have been no treatment options approved for Acute Spinal Cord Injury (ASCI) by either the Food a...

Rapid expansion in coverage over the coming years will see the Filipino seasonal influenza vaccine market quadruple in size by 2018

Rapid expansion in coverage over the coming years will see the Filipino seasonal influenza vaccine market quadruple in size by 2018, states the latest report from business intelligence providers GBI Research. According to the firm’s latest healthcare research*, revenue for the Filipino seasonal influenza vaccine market is forecast to rocket from US$107m in 2012 to US$454m in 2018, repres...

Records exposing the level of medical device recalls made in the US have sparked calls for stricter regulations

Records exposing the level of medical device recalls made in the US, and therefore the multitude of serious health risks patients have been subjected to over the past few years, have sparked calls for stricter regulations, according to a new report by healthcare intelligence company GBI research. The new report* suggests that individuals with heart problems are most at risk of health problems...

GBI Research - latest research on “Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies”

GBI Research, the leading business intelligence provider, has released its latest research on “Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies”, which provides insights into neurometabolic disease therapeutics market until 2017. The report is built using data and information so...

Edison - Consort Medical - Company outlook - Inhaling is to be encouraged

April 23rd 2013: Consort Medical’s outlook now rests on the Bespak division, but new product visibility has traditionally been low and the commercial prospects of the pipeline have been difficult to assess. Three recent posters (presented at a Boston symposium) have drawn our attention to the Oxette nicotine inhaler device and we detail them in this note. We believe Oxette could become...

New appointment extends Freeman Technology’s applications team

22 April 2013: Tewkesbury, UK: Powder characterization company Freeman Technology has appointed Doug Millington-Smith in the role of Applications Specialist. Educated to PhD level, Doug has a background in chemistry and considerable experience in supporting the use of high precision scientific instrumentation. He is based at Freeman Technology’s headquarters in the UK and will be involv...

ModiQuest Announces Publication of its Novel Anti-Citrullinated Protein Antibodies for Rheumatoid Arthritis

April 23, 2013 – Oss, The Netherlands.  ModiQuest BV, a Dutch antibody drug development and diagnostics company focused on chronic inflammatory diseases, today announced the publication of novel therapeutic antibodies for the treatment of rheumatoid arthritis.  The results were published in the Journal of Clinical & Cellular Immunology 2013; S6: 006. doi: 10.4172/2155-9899...

Conference Alert: Inaugural Digital Health Forum 2013 (DHF13),Royal Society of Medicine, London, UK, 11 June 2013

London, UK – 23 April 2013 – Connect Digital Health, an industry organisation dedicated to promoting the development of digital tools to improve healthcare outcomes, has drawn together leaders in the digital health industry to launch a new invitation-only conference, Digital Health Forum 2013 (DHF13), as a new platform for investors and industry to meet to create new partnerships....

Global economic benefits of GM crops (GMO) reach almost $100 billlion

Press release: 22 April 2013: Dorchester, UK:  In the sixteenth year of widespread adoption, crop biotechnology has delivered an unparalleled level of farm income benefit to the farmers, as well as providing considerable environmental benefits to both farmers and citizens of countries where the technology is used. "Where farmers have been given the choice of growing GM crops, ado...

Cultural and social modesty is leaving women uncomfortable discussing Postmenopausal Vaginal Atrophy (PVA) – a condition which goes underdiagnosed worldwide

The new report* found that up to 50% of postmenopausal women experience symptoms of vaginal atrophy, but only a quarter of these individuals seek medical treatment, and cultural and social attitudes toward sexuality and aging play a huge role in this. The urogenital tract, including the vagina, bladder and pelvic floor muscles, contains estrogen receptors, and so estrogen depletion causes dete...

Fungal nail infections pose a global health threat, with over 50 million people suffering from the contagious condition last year

The new report* predicts that prevalent cases of dermatophytic onychomycosis (DO) across US, France, Germany, Italy, Spain, UK, and Japan will increase by a further 15% over the next decade, from 51.50 million cases in 2012 to 59.17 million cases by 2022. GlobalData epidemiologists forecast that the US alone will see prevalent cases of DO rise from 31.66 million cases in 2012 to 37.69 million...

National healthcare practices affect the diagnosis rate and survival rate of any disease, and CF patients can sometimes experience substantially different lives depending on the country they are born and treated in.

The new report* shows that CF patients in the US are more likely to live well into adulthood compared to several decades ago, and expect a median survival age of 37 years, showing a dramatic improvement of over the last 25 years. The CF patient population’s average survival age in the US has steadily increased due to early diagnosis and treatment with all 50 states screening for CF in ne...

Sirtex Medical - Edison Investment Report

Sirtex could see a step change in the use of SIR-spheres, which are already growing fast despite being deployed as a last-line salvage therapy in hepatocellular carcinoma (HCC), if results from a series of Phase III studies over the next three years support earlier usage. The first of these, SIRFLOX in liver metastases arising from colorectal cancer (CRC), has just completed recruitment and shou...

Addex Therapeutics - New orphan disease focus - Edison

Published on 8 Apr 2013: Addex Therapeutics is a Swiss biotech company with a proprietary allosteric modulator discovery platform and a pipeline in rare (orphan) disease indications. Following a strategic review, Addex is now focused on developing its clinical-stage pipeline in orphan disease indications. The restructuring of research operations has freed up financial resources to impl...

Vectura - Product pipeline and share price performance - Edison

Published on 16 Apr 2013: Vectura is a UK speciality pharmaceutical company developing a range of inhaled therapies and technologies, principally for the treatment of respiratory diseases such as asthma and COPD. Vectura has a late-stage pipeline of products in development for COPD, a portfolio of generic copy versions of existing inhaled drugs and technologies, including inhalers and...

Forbion Capital Partners co-leads Euro 15 Million Series A Financing for Allecra Therapeutics

Financing for development of novel antibiotic treatments in partnership with Orchid Chemicals & Pharmaceuticals Ltd. Munich, Germany and Naarden, The Netherlands, 18 April 2013 – Forbion Capital Partners, the Dutch life sciences venture capital firm, today announced that it has co-led the €15 million Series A financing round for Allecra Therapeutics GmbH, together with E...

BioGasol ApS Delivers its First Commercial Pretreatment System to Sweetwater Energy

Copenhagen, Denmark – 18 April, 2013 – BioGasol ApS, the renewable energy company, today announced the delivery of its first commercial biomass pretreatment system to US-based Sweetwater Energy, Inc. The cellulosic sugar producer will use the unit, a Carbofrac™ 10, in its demonstration facility to produce pretreated biomass for use in downstream processes. BioGasol’s...

Malvern Instruments experts contribute presentation, run DLS short course and exhibit at PEGS 2013

17 April 2013: Malvern, UK:  Contributing to the Analytical and Purification Streams at the protein engineering summit PEGS 2013, Dr Kevin Mattison, Principal Scientist, Bioanalytics, at Malvern Instruments will present a paper on ‘Avoiding Aggregation and Viscosity Challenges – Early Development Formulation Screening’. He will also be one of the instructors on Malvern&...

AmpliPhi and Intrexon collaborate for new generation bacteriophage-based therapies

     Combined Expertise to Create New Generation of Bacteriophage-Based Therapeutics For Antibiotic Resistant Infections Richmond, VA, and Germantown, MD, April 16, 2013 – AmpliPhi BioSciences Corp. (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, and Intrexon Corporation, a synthetic biology co...

Copley Scientific to showcase new accessories for inhaled product testing at RDD Europe 2013

16 April 2013: Nottingham, UK: Copley Scientific will present a new range of standard, off-the-shelf mouthpiece adapters for routine testing of a number of commercially available inhalers at Respiratory Drug Delivery (RDD) Europe 2013 (May 21-24, Berlin, Germany). Designed to interface with both dose uniformity sampling apparatus (DUSA) and the cascade impactors used for aerodynamic particle...

DySIS Medical receives £7.4m of additional funding.

Company gains new investor Edinburgh 15 April 2013: DySIS Medical Ltd, a medical devices company active within women's health, today announces the completion of a £7.4 million (gross) fundraising. The investment is comprised of £6 million from Copenhagen-based, Lundbeckfond Ventures, an investment group specialising in Life Sciences. A further £1.4 million was raised...

Recruitment in World's Largest Interventional Oncology Study Completed

500-plus Patient Study Aimed At Expanding Use of Targeted Liver Cancer Therapy Called SIR-Spheres Microspheres as a First-Line Treatment for Colorectal Liver Metastases SYDNEY Australia, 15 April 2013: Australian-based global oncology company, Sirtex Medical Limited (ASX: SRX), has announced the completion of patient recruitment for its global SIRFLOX clinical study which is aimed at expand...

Medtech industry executives to reveal strategies for gaining a competitive edge in keynote panel at EuroMedtech™ 2013.

Zurich, Switzerland and Duesseldorf, Germany – April 11, 2013: The fifth annual EuroMedtech™ partnering conference to be held May 7–8 in Duesseldorf, Germany will feature executive panelists who will share insight on business development models and strategies for success in the medtech industry. As the leading partnering event for medical devices and technology, the conferen...

Roche posts a 5% rise in first quarter sales- comment from Ana Nicholls, Healthcare Analyst at The Economist Intelligence Unit.

"While its rivals are suffering from generic competition, Roche remains comparatively immune. The difficult operating environment in Europe is taking a slight toll - revenue growth is markedly slower than the double-digit growth Roche was reporting a few years ago. Nevertheless, a strong pipeline of drugs, particularly for cancer, and low risks from patent expiry mean the company is emergin...